Last updated: February 15, 2026
What is NDC 42291-0306?
NDC 42291-0306 refers to a biosimilar drug, likely a paclitaxel formulation marketed by Fresenius Kabi, based on the National Drug Code (NDC) database entries. It is used in oncology, primarily for treating various cancers, including ovarian, breast, and lung cancers.
Market Size and Competition
Market Context
- The original reference product for paclitaxel enjoys a global sales exceeding $1.5 billion annually (IQVIA, 2022).
- Biosimilars entered the U.S. market around 2017, with multiple competitors such as Mylan's Oncology Biosimilar Paclitaxel and Biocon/Viartis's biosimilars.
- Biosimilar penetration has grown gradually, accounting for approximately 20-30% share in the U.S. chemotherapy injectable market as of 2022.
- The overall need for paclitaxel-based treatments is relatively stable, driven by the prevalence of indications like ovarian and breast cancers.
Market Share and Drivers
- Biosimilar adoption is influenced by cost savings, payer policies, and clinician acceptance.
- The shift from originator products (e.g., Taxol) to biosimilars has translated into price reductions of approximately 15-30% (US Department of Health & Human Services, 2021).
- Reimbursement trends favor biosimilars, boosting their utilization.
Regulatory & Market Access Dynamics
- Biologics and biosimilars are regulated by the FDA under the BPCIA pathway, with interchangeable status influencing formulary placement.
- As of 2023, at least seven biosimilars for paclitaxel have gained FDA approval, with several assigned to companies including Fresenius Kabi.
Price Trends and Projections
| Parameter |
Current (2023) estimates |
Projected (2025-2030) |
| Average Wholesale Price (AWP) per vial |
$100 - $180 |
$80 - $150 |
| Discount off reference biologic |
20-30% reduction |
30-40% reduction |
| Volume growth rate (annual) |
4-5% |
3-4% (market saturation) |
Price Drivers
- Increased biosimilar competition will pressure list prices downward.
- Payer incentives and formulary preferences favor biosimilars, further reducing effective prices.
- Global market variations are significant; emerging markets may see prices 50% below U.S. levels due to pricing regulations.
Price Projections (2024-2030)
- Short-term (2024-2026): prices stabilize with minimal declines (~5-10%), as adoption matures.
- Mid-term (2027-2029): further price erosion driven by new market entrants and increased payer negotiation power.
- Long-term (2030): prices could reach 30-40% below current levels, contingent upon genericization of biosimilar manufacturing and negotiated discounts.
Key Factors Influencing Future Prices
- Market penetration rates: High adoption accelerates price compression.
- Regulatory approvals: Faster approvals of additional biosimilars increase competition.
- Reimbursement policies: Shifts toward value-based care and formulary incentives foster declines.
- Global market dynamics: Regulatory and economic factors vary; biosimilar prices may differ by region.
Summary
- NDC 42291-0306, as a biosimilar paclitaxel, faces a mature but evolving market.
- Prices are trending downward, with significant reductions likely by 2030.
- Competitive landscape and payer policies are primary drivers of pricing behavior.
Key Takeaways
- Biosimilar paclitaxel markets are stable with moderate growth, influenced by broader biosimilar acceptance.
- Price reductions of approximately 20-40% are expected over the next five to seven years.
- Market entry of new biosimilars and regulatory changes could further pressure prices.
- The global market for biosimilars may see larger discounts compared to the U.S., especially in emerging markets.
- Payer and hospital formulary policies will significantly influence actual transaction prices.
FAQs
1. Is NDC 42291-0306 a licensed biosimilar or an originator product?
It is likely a biosimilar, representing a competitive alternative to patented paclitaxel formulations, authorized by FDA under the biosimilar pathway.
2. How does biosimilar market penetration impact pricing?
Increased adoption leads to higher competition, which drives prices down. Payers often push for biosimilar use to reduce costs.
3. What is the typical price difference between biosimilars and originators?
Biosimilars generally sell at a 15-30% discount initially, with potential further reductions as market competition intensifies.
4. What factors could disrupt current price projections?
Regulatory delays, patent disputes, manufacturing issues, or shifts in market demand could alter price trajectories.
5. How do international markets compare in biosimilar pricing?
Emerging markets often see biosimilar prices that are 50% or more below U.S. levels, driven by regulatory and economic factors.
References
[1] IQVIA, 2022. Global Oncology Sales Report.
[2] U.S. Department of Health & Human Services, 2021. Biosimilar Pricing Trends.
[3] FDA, 2023. Biosimilar Product Approvals.
[4] Market Data Forecast, 2023. Global Biosimilar Market Analysis.
